Polymer-factor VIII-von Willebrand factor-conjugates

Details Polymer-factor VIII-von Willebrand factor-conjugates Polymer-factor VIII-von Willebrand factor-conjugates

2011-02-08

2011-02-08

Hobbs, Lisa J (Department: 1657)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C525S054100, C530S383000

Reexamination Certificate

active

07884075

ABSTRACT:
The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4757006 (1988-07-01), Toole, Jr. et al.
patent: 4877608 (1989-10-01), Lee et al.
patent: 4965199 (1990-10-01), Capon et al.
patent: 4970300 (1990-11-01), Fulton et al.
patent: 5122614 (1992-06-01), Zalipsky
patent: 5298643 (1994-03-01), Greenwald
patent: 5328694 (1994-07-01), Schwinn
patent: 5470954 (1995-11-01), Neslund et al.
patent: 5539063 (1996-07-01), Hakimi et al.
patent: 5565427 (1996-10-01), Freudenberg
patent: 5605884 (1997-02-01), Lee et al.
patent: 5618788 (1997-04-01), Capon et al.
patent: 5621039 (1997-04-01), Hallahan et al.
patent: 5733873 (1998-03-01), Osterberg et al.
patent: 5763401 (1998-06-01), Nayar
patent: 5846951 (1998-12-01), Gregoriadis
patent: 6005077 (1999-12-01), Schwarz et al.
patent: 6037452 (2000-03-01), Minamino et al.
patent: 6379933 (2002-04-01), Jonson et al.
patent: 6455639 (2002-09-01), Yasukohchi et al.
patent: 6566506 (2003-05-01), Greenwald et al.
patent: 6586573 (2003-07-01), Besman et al.
patent: 6864350 (2005-03-01), Harris
patent: 7199223 (2007-04-01), Bossard et al.
patent: 2004/0132640 (2004-07-01), DeFrees et al.
patent: 2004/0247624 (2004-12-01), Unger et al.
patent: 2006/0160948 (2006-07-01), Scheiflinger et al.
patent: 0 774 261 (1997-05-01), None
patent: 0 784 632 (1999-01-01), None
patent: 0 977 584 (2001-12-01), None
patent: 1 258 497 (2002-11-01), None
patent: 1 260 582 (2002-11-01), None
patent: 86/06096 (1986-10-01), None
patent: WO 93/00357 (1993-01-01), None
patent: WO 94/15625 (1994-07-01), None
patent: WO 9415625 (1994-07-01), None
patent: WO 94/29370 (1994-12-01), None
patent: WO 97/11957 (1997-04-01), None
patent: WO 97/19701 (1997-06-01), None
patent: 98/25969 (1998-06-01), None
patent: 98/38219 (1998-09-01), None
patent: 00/49047 (2000-08-01), None
patent: WO 01/05434 (2001-01-01), None
patent: WO 01/37893 (2001-05-01), None
patent: 03/040211 (2003-05-01), None
patent: WO 2004/075923 (2004-09-01), None
patent: WO 2004/081053 (2004-09-01), None
patent: WO 2005/032581 (2005-04-01), None
patent: WO 2005/058366 (2005-06-01), None
Avigad et al.;J. Biol. Chem.; 237; pp. 2736-2743 (1962).
Bi, et al.;Nat. Genet.; 10; pp. 119-121 (1995).
Brown et Bosak;Thromb. Res.; 43; pp. 303-311 (1986).
Denis, C., et al.;Proceedings of the National Academy of Sciences USA; vol. 95; pp. 9524-9529 (1998).
De Romeuf et Mazurier;Thromb. Hamost.; 69; pp. 436-440 (1993).
Elödi, et al.;Thromb. Res.; 21; pp. 695-700 (1981).
European Pharmacopoeia (Ph. Eur.) 3rd Ed.; 2.7.4 (1997).
Favaloro;Thromb. Haemost.; 83; pp. 127-135 (2000).
Fernandes et Gregoriadis;Biochem. Biophys. Acta; 1341; pp. 26-34 (1997).
Fischer, B.E., et al.;Cellular and Molecular Life Science; No. 53; pp. 943-950 (1997).
Fischer, B., et al.;FEBS Letters 351; pp. 345-348 (1994).
Fischer, B.E., et al.;FEBS Letters 375; pp. 259-262 (1995).
Girma et al.;Thromb. Haemost.; 74; pp. 156-160 (1995).
Jennings et Lugowski;J. Immunol.; 127; pp. 1011-1018 (1981).
Kaersgaard et Barington;J. Chromatogr.; B715; pp. 357-367 (1998).
Lankhof et al.;Thromb. Haemost.; 77; pp. 1008-1013 (1997).
Lee et al.;Pharm. Res.; 20; pp. 818-825 (2003).
Lenting, P.J., et al.;The Journal of Biological Chemistry; vol. 279:13; pp. 12102-12109 (2004).
Macfarlane et al.;Thromb. Diath. Haemorrh.; 34; pp. 306-308 (1975).
Migneault et al.;Biotechniques; 37; pp. 790-796 (2004).
Pietu et al.;Biochem. Biophys. Res. Commun.; 164; pp. 1339-1347 (1989).
Roberts et al.;Advanced Drug Delivery Reviews; 54; pp. 459-476 (2002).
Roussi, J., et al.;Blood Coagulation and Fibrinolysis; vol. 9:4; pp. 361-372 (1998).
Ruggeri et al.;Blood; vol. 57; No. 6; pp. 1140-1143 (1981).
Ruggeri et al.;Thromb. Haemost.; 82; pp. 576-584 (1999).
Schlokat, U., et al.;Biotechnology and Applied Biochemistry; vol. 24; pp. 257-267 (1996).
Schwarz, H.P., et al.;Haemophilia; vol. 4:3; pp. 53-62 (1998).
Schwarz, H.P., et al.;Seminars in Thrombosis and Hemostasis; vol. 28:2; pp. 215-225 (2002).
Turecek et al.;Semin. Thromb. Hemost.; 28 ; pp. 149-160 (2002).
Turecek, P.L., et al.;Blood; vol. 90:9; pp. 3555-3567 (1997).
Weiss, H.J., et al.;The Journal of Clinical Investigation; vol. 52; pp. 2708-2716 (1973).
Wilchek et. Bayer;Meth. Enzylmol.; 138; pp. 429-442 (1987).
Office Action in U.S. Appl. No. 12/184,567, mailed Dec. 29, 2008.
Blood coagulation factor derivatives with side chain of amino acids moiety bound via coupling agent to poly:alkylene glycol [abstract], Derwent, Sep. 29, 1984, (JP 01 742043, Nippon Chemiphar Co., Mar. 15, 1993).
Gregoriadis et al., Polysialic acids: potential in drug delivery, FEBS Lett., 315:271-276, 1993.
Gregoriadis et al., Polysialic acids: potential in improving the stability and pharmokinetics of proteins and other therapeutics, CMLS Cell. Mol. Life Sci., 57:1964-1969, 2000.
Gregoriadis et al., Polysialylated proteins: an approach to improving enzyme stability and half-life in the blood circulation, Sciences Techniques et Pratiques STP, 9:61-66, 1999.
International Search Report, PCT/US2005/046879, European Patent Office, mailed Jun. 19, 2007.
Jain et al., Polysialylated insulin: synthesis, characterization and biological activity in vivo, Biochim. Biophys. Acta, 1622:42-49, 2003.
Jain et al., Polysialylation: the natural was to improve the stability and pharmacokinetics of protein and peptide drugs, DDS&S, 4:3-9, 2004.
Lewis et al., A facile, water-soluble method for modification of proteins with DOTA: use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates, Bioconj. Chem., 6:565-576, 1994.
Luo et al., A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells [abstract], Biomacromolecules, 1:208-218, 2000.
Luo et al., Synthesis and selective cytotoxicity of a hyaluronic acid-antitumorbioconjugate [abstract], Bioconj. Chem., 10:755-763, 1999.
Saenko et al., Strategies towards a longer acting factor VIII, Haemophilia, 12:42-51, 2006.
Turecek et al., Modification of rVWF with polysialic acid: biochemical and functional characterization in mice with VWD, Blood, 108:298A-299A, 2006.
Turecek et al., PDG modified rVFW prolongs the survival of native rFVIII in hemophilia A knock-out mice, Blood, 108:299A, 2006.
Written Opinion of the International Searching Authority, PCT/US2005/046879, European Patent Office, mailed Jun. 19, 2007.

Affiliated with

Also associated with

Rating

Polymer-factor VIII-von Willebrand factor-conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polymer-factor VIII-von Willebrand factor-conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymer-factor VIII-von Willebrand factor-conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2631918